Monopar Therapeutics MNPR Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept mnpr:IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's increase decrease in operating lease right of use assets and liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's increase decrease in operating lease right of use assets and liabilities?
- Monopar Therapeutics (MNPR) reported increase decrease in operating lease right of use assets and liabilities of $25 in Q1 2026.
- How has Monopar Therapeutics's increase decrease in operating lease right of use assets and liabilities changed year-over-year?
- Monopar Therapeutics's increase decrease in operating lease right of use assets and liabilities decreased by 97.1% year-over-year, from $850 to $25.
- What does increase decrease in operating lease right of use assets and liabilities mean?
- This metric tracks the net change in the balance sheet value of operating lease assets and their corresponding liabilities. It reflects the impact of lease renewals, terminations, or modifications on the company's long-term financial obligations. Monitoring this helps investors understand the company's commitment to physical infrastructure and its impact on future cash outflows.